(Press-News.org) Researchers who lead the world’s first comprehensive sequencing program for newborn infants have published the next chapter in the ongoing study of the BabySeq Project, with new findings on infants and families who have been followed for 3-5 years. In a study published today in the American Journal of Human Genetics, researchers from Mass General Brigham and Boston Children’s Hospital reported that over 10 percent of the first 159 infants to undergo screening through DNA sequencing were discovered to have unanticipated mutations in disease-associated genes, all of which were medically actionable, meaning that the child would likely benefit from early treatment or surveillance. When their families were followed over the next five years, these findings prompted genetic testing, specialty consultations and even procedures among infants’ at-risk family members. Most striking, the at-risk mothers of three infants identified with previously unrecognized elevated risk for adult-onset cancer chose to undertake risk-reducing surgeries.
"By screening apparently healthy newborns, entire families were alerted for the first time that dangerous but treatable genetic variants were present,” said corresponding author Robert C. Green, MD, MPH, a physician-scientist at Brigham and Women’s Hospital and professor of genetics at Harvard Medical School, who co-leads the BabySeq Project. “We were stunned to see that with no specific guidance from the study, newborn sequencing prompted life-saving actions among several mothers.”
Babies born in U.S. hospitals currently undergo routine newborn screening, a laboratory test to identify the risk of up to 60 treatable conditions. But hundreds of additional genetic disorders, including a growing number of devastating childhood diseases, now have targeted treatments, including gene and cell therapies that can offer permanent prevention or cures. With these developments, the implementation of newborn DNA sequencing has taken on greater urgency.
The BabySeq Project is a first-of-its-kind randomized clinical trial begun as a collaboration between Brigham and Women’s Hospital (BWH) and Boston Children’s Hospital (BCH), and which expanded to include Massachusetts General Hospital (MGH). The trial was designed to examine how best to use genomics in clinical newborn medicine. The first phase of the study enrolled 325 infants and families from well-baby nurseries and newborn nursery at BWH and neonatal intensive care units at BWH, BCH, and MGH between 2013 and 2018. Half of the newborns received genomic sequencing with comprehensive interpretation and return of results for nearly 1,000 genes. The sequencing looked for variants related to genetic risk for childhood-onset and childhood-actionable conditions, as well as several highly actionable adult-onset conditions that could only be inherited from one of the parents. The families have been followed for 3-5 years to understand medical, behavioral and economic outcomes.
Sequencing newborn DNA not only revealed the risk of future disease, but in some cases uncovered hidden conditions that were already present. For example, in one of the healthy newborns enrolled in the study, researchers detected a harmful change in the ELN gene, which can cause supravalvular aortic stenosis, a condition that if untreated, could lead to heart failure. On follow-up testing, a previously unsuspected narrowing of the aorta was detected. “Both our research team and the family were surprised that a DNA test led to the discovery of an anatomical abnormality in this baby,” said co-lead author Nidhi Shah, MD, a medical geneticist at Dartmouth Health Children's, and collaborator with the Genomes2People Research Program. “This case highlights how genomic screening can uncover treatable genetic conditions that may not be apparent to healthcare providers during routine pediatric care.”
“The results of this study indicate that conducting thorough genetic sequencing of newborns has the potential to significantly improve health outcomes for infants and their families.” said Alan Beggs, PhD, Director of The Manton Center for Orphan Disease Research at Boston Children’s Hospital, and co-leader of this BabySeq Project. Rare disease experts agree. In a separate study recently published by BabySeq investigators, a remarkable 88% of rare disease experts agreed that DNA sequencing to screen for treatable childhood disorders should be made available to all newborns.
The BabySeq Project has published extensively on the impact of newborn sequencing and, as part of BabySeq2, is currently enrolling newborns in multiple cities, prioritizing inclusion of a diverse, nationally representative cohort of families.
Paper cited: Green et al. “Actionability and Medical Evaluation of Unanticipated Monogenic Disease Risks in Newborn Genomic Screening: Findings from the BabySeq Project,” American Journal of Human Genetics, DOI: 10.1016/j.ajhg.2023.05.007.
Funding: This work was funded by the National Institutes of Health (HD077671, TR003201).
Disclosures: Dr. Green has received compensation for advising Allelica, Atria, Fabric, Genome Web and Genomic Life and is co-founder of Genome Medical and Nurture Genomics. Additional disclosures for co-authors can be found in the AJHG paper.
About Genomes2People, BabySeq Project and Precision Population Health at Ariadne Labs: Mass General Brigham is an integrated academic health care system, one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School, uniting great minds in medicine to make life-changing impact for patients in our communities and people around the world. The Genomes2People Research Program at Brigham and Women’s Hospital, the Broad Institute, Ariadne Labs and Harvard Medical School explores the medical, behavioral and economic outcomes of integrating genomic information into medicine and society. The NIH-funded BabySeq Project is the world’s first project to introduce comprehensive DNA sequencing for apparently healthy infants and has published extensively on medical benefits, psychosocial outcomes and medical costs associated with newborn sequencing. Precision Population Health is a collaboration between Genomes2People and Ariadne Labs that aims to bring the power of genomic medicine to primary care settings, in order to prevent diseases before they occur.
About Mass General Brigham: Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
About Boston Children’s Hospital
Boston Children’s Hospital is ranked the #1 children’s hospital in the nation by U.S. News & World Report and is a pediatric teaching affiliate of Harvard Medical School. Home to the world’s largest research enterprise based at a pediatric medical center, its discoveries have benefited both children and adults since 1869. Today, 3,000 researchers and scientific staff, including 11 members of the National Academy of Sciences, 24 members of the National Academy of Medicine and 9 Howard Hughes Medical Investigators comprise Boston Children’s research community. Founded as a 20-bed hospital for children, Boston Children’s is now a 485-bed comprehensive center for pediatric and adolescent health care. For more, visit our Answers blog, and follow us on social media: @BostonChildrens, @BCH_Innovation, Facebook, YouTube and Instagram.
END
DNA sequencing in newborns reveals years of actionable findings for infants and families
2023-06-05
ELSE PRESS RELEASES FROM THIS DATE:
Tirzepatide has unique activity to stimulate insulin secretion
2023-06-05
DURHAM, N.C. – Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.
The finding, reported June 5 in the journal Nature Metabolism, is the first study to use cells from human donors to demonstrate how tirzepatide stimulates insulin secretion, an important action utilized by this drug to lower blood glucose in patients with type 2 diabetes.
“Understanding the potential of drugs ...
ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma
2023-06-05
CHICAGO – Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Data from the study were presented today by Jason Westin, M.D., director of clinical research in the Department of Lymphoma and Myeloma, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and published concurrently in ...
Doctors test chest pain medication to treat hot flashes
2023-06-05
Women have long searched for remedies for the bothersome hot flashes that often come with menopause.
In a novel investigation, researchers at UC San Francisco tested the benefits of continuously wearing a nitroglycerin patch – an established treatment for chest pain from coronary artery disease – for menopausal women experiencing at least seven hot flashes a day. Unlike most treatments for hot flashes that target brain mechanisms, nitroglycerin works on blood vessels throughout the body.
The results were mixed. While ...
Scientists expand understanding of limb evolution in earliest birds
2023-06-05
The assembly of the volant bird body plan from the ancestral bulky dinosaurian condition is an enduring topic of evolutionary biology. The body plan of volant birds demonstrates a pronounced decrease in body size and proportionate elongation of the forelimbs. Given the scaling relationship between limb and body size, changes to the former were likely clouded by changes to the entire body size.
Since changes to individual limb elements provides the direct basis for natural selection, they are essential to comprehending branch- and lineage-specific evolutionary patterns across the transition from terrestrial to ...
Tracing Chile’s indigenous roots through genetics and linguistics
2023-06-05
How do today’s indigenous communities of South America trace back to the history of human migration and contact in the continent? An international team has worked to reconstruct the legacy of Chile’s largest indigenous community, the Mapuche, in a quest to strengthen their representation in the history of the continent. It appears the Mapuche long lived in relative isolation but do bear some influences from other populations of the Central Andes and the far south of Chile.
South America was the last continent ...
Pumping the brakes on autoimmune disease
2023-06-05
LA JOLLA, CALIF. – June 5, 2023 – Researchers at Sanford Burnham Prebys, collaborating with scientists from Eli Lilly and Company, have revealed the structure and function of a drug called LY3361237, which can reduce the harmful activity of the immune system to help treat autoimmune diseases. Their work laid the foundation for a new treatment that’s currently in a Phase 2 clinical trial for lupus, an autoimmune disease affecting multiple organs in the body. The study is published in Structure, a Cell Press journal.
The ...
Scientists use machine learning to ‘see’ how the brain adapts to different environments
2023-06-05
FOR IMMEDIATE RELEASE
Johns Hopkins scientists have developed a method involving artificial intelligence to visualize and track changes in the strength of synapses — the connection points through which nerve cells in the brain communicate — in live animals. The technique, described in Nature Methods, should lead, the scientists say, to a better understanding of how such connections in human brains change with learning, aging, injury and disease.
“If you want to learn more about how an orchestra plays, you have to watch individual players over time, and this ...
Cancer discoveries could enhance immunotherapy, breast cancer care
2023-06-05
Two new discoveries from the Dudley lab at UVA Cancer Center highlight the different roles of blood vessels in solid tumors – and the findings could help prevent breast cancer from spreading and enhance the effectiveness of one of the most important new cancer treatments in many years.
In one new scientific paper, researcher Andrew C. Dudley, PhD, and his team report that the effectiveness of immunotherapy drugs called immune check blockade is enhanced when blood vessels are targeted in a specific way. (Immunotherapy enhances the power of the immune system to fight cancer and other diseases.) In another paper, published ...
Refining surge protector in crops could boost yields
2023-06-05
Awash in a rowed sea of its brethren, a corn leaf relegated to the lowest rung of its stem spends much of a June afternoon doused in shade cast by the higher-ups.
Then a gust begins pushing, pulling and twisting the waxy wings in concert, cracking a window to the fireball roiling 93 million miles away. It’s a prime, precious opportunity for photosynthesis to transform the sunlight into food. Unfortunately, the photosynthetic equivalent of a surge protector — one evolved to help plants mitigate damage driven by sudden spikes of high-intensity light — is slow to reset after so much time in the shade. The gust dissipates, the moment ...
Moving towards a more inclusive approach to medicine
2023-06-05
Moving towards a more inclusive approach to medicine
Release of pangenome representing wide diversity of individuals ushers in new understanding of human biology and disease
The first human genome, which has served as the reference until now, was released approximately 20 years ago. It was a landmark accomplishment that had a huge impact on biomedical research and changed the way scientists study human biology. But it was based on just a few individuals and did not capture the full genetic diversity of the human population.
An important step forward for both biology and biomedical research
“Since ...